Summary & Overview
HCPCS Level II J1073: Testosterone Pellet Implant, 75 mg
HCPCS Level II code J1073 identifies a 75 mg testosterone pellet implant used in hormone replacement and related clinical care. This supply code is relevant nationally for clinicians and billing teams managing implantable testosterone therapy and for payers overseeing coverage of hormone delivery devices. The code matters because it standardizes reporting for a commonly used formulation in long-acting testosterone therapy.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of billing and clinical context for the product, typical sites of service where the implant is placed, and what to expect in payer coverage discussions. The publication outlines common benchmarking topics such as utilization patterns, pricing considerations, and coding practices tied to implantable testosterone products where available.
This summary equips revenue cycle staff, clinicians, and policy analysts with the core facts about HCPCS Level II code J1073, clarifies the clinical service type (hormone implant therapy), and highlights areas addressed in the full publication: national coverage context, coding nuances, and operational considerations for outpatient and ambulatory settings.
Billing Code Overview
HCPCS Level II code J1073 represents testosterone pellet, implant, 75 mg. This item is used for subcutaneous or intramuscular implant therapy delivering a defined 75 mg dose of testosterone.
Service Type: Hormone implant therapy
Typical Site of Service: Outpatient clinic, physician office, or ambulatory surgical setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a middle-aged or older adult assigned male at birth with symptoms of testosterone deficiency such as decreased libido, fatigue, loss of muscle mass, and/or osteoporosis, or a patient undergoing gender-affirming masculinization. The clinician documents baseline serum total testosterone, luteinizing hormone, and relevant labs (CBC, PSA in men >40 when indicated) before initiating therapy. After shared decision-making, the clinician schedules an in‑office procedure for subcutaneous insertion of a J1073 testosterone pellet (75 mg) under local anesthesia in an outpatient clinic, ambulatory surgical center, or physician office. The workflow includes informed consent, verification of preprocedure labs and medications (anticoagulants), sterile preparation, local anesthetic infiltration, small skin incision and subcutaneous pocket creation, placement of one or more pellets, wound closure with adhesive strips or suture, and postprocedure observation with discharge instructions for wound care, activity restrictions, and follow-up testosterone level monitoring. Typical sites of service are office-based outpatient clinics, ambulatory surgical centers, and outpatient procedural suites where minor surgical implants are performed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 |